Tonix plans to initiate a randomized, double-blind, placebo-controlled Phase 2 field study in the first half of 2027, pending FDA clearance. This study will evaluate the efficacy of a single subcutaneous dose of TNX-4800 in preventing confirmed Lyme disease during the primary efficacy surveillance period. The primary endpoint will focus on the prevention of Lyme disease at four months, with a key secondary endpoint assessing prevention at six months.
The Phase 1 study involved 44 healthy adult subjects, with 41 completing the trial. Results showed no significant safety signals, and serum TNX-4800 levels were measurable as early as two days post-administration, indicating rapid absorption. The study's findings support Tonix's strategy to conduct further clinical investigations, with the expectation of having GMP investigational product available for testing in early 2027. The company also plans to initiate a controlled human infection model study in 2028 if necessary.
Tonix's CEO, Dr. Seth Lederman, emphasized the potential of TNX-4800 to provide a preventative option for the estimated 87 million people in the U.S. at high risk of contracting Lyme disease. Unlike traditional vaccines that require complex immunization schedules, TNX-4800 aims to offer protection within two days of administration, making it a potentially more accessible option for individuals in Lyme-endemic areas. The company believes that TNX-4800's unique characteristics could significantly improve the landscape of Lyme disease prevention.
